Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society...

Related Keywords

Boston ,Massachusetts ,United States ,Canada ,Canadian ,Amanda Cray ,Dmitri Bobilev ,John Valliant ,Fusion Pharmaceuticals Inc ,Prnewswire Fusion Pharmaceuticals Inc ,Investor Relations Corporate Communications ,Drug Administration ,Fusion Pharmaceuticals ,Nasdaq ,Niowave Inc ,Astrazeneca ,Exchange Commission ,Society Of Nuclear Medicine ,Nuclear Medicine ,Molecular Imaging ,Federated Hermes Kaufmann Funds ,Executive Officer John Valliant ,Annual Meeting ,Medical Officer Dmitri Bobilev ,Securities Act ,Response Inhibitors ,Private Securities Litigation Reform Act ,Investor Relations ,